Pretreatment Total Testosterone Level Predicts Pathological Stage in Patients With Localized Prostate Cancer Treated With Radical ProstatectomyJason C. Massengill, Timothy F. Donahue, Leon Sun et al.|The Journal of Urology|2003Cited by 293
Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: An overview of the Department of Defense Center for Prostate Disease Research national databaseJudd W. Moul, Norman M. Rich, Hongyu Wu et al.|Surgery|2002Cited by 101
Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen EraCorey A. Carter, Judd W. Moul, Timothy F. Donahue et al.|Journal of Clinical Oncology|2003Cited by 81
Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the center for prostate disease research nomogramsKevin J Gancarczyk, Judd W. Moul, Hongyu Wu et al.|Urology|2003Cited by 79
Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the department of defense (DOD) Center for Prostate Disease Research (CPDR) national databaseJudd W. Moul, Timothy F. Donahue, Leon Sun et al.|Urologic Oncology Seminars and Original Investigations|2003Cited by 26